Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

33

DUBLIN–(BUSINESS WIRE)–Horizon submitted a BLA to the U.S. FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease…

 

 

http://www.businesswire.com/news/home/20190710005253/en/Horizon-Therapeutics-plc-Submits-Teprotumumab-Biologics-License